Mount Sinai Innovation Partners

02/27/2025

A recent study led by Ipek Ensari, PhD, Assistant Professor in the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai, shows that physical activity has major mental health benefits for women with chronic pelvic pain disorders, including endometriosis and uterine fibroids. Learn more from Medical Xpress:

A new Mount Sinai study provides compelling evidence that exercise can significantly help the mental well-being of millions of women living with chronic pelvic pain disorders (CPPDs), such as endometriosis and uterine fibroids.

02/25/2025

Have you met the latest Elementa Labs cohort? Learn all about OBELAB, Medwise AI, and TAILRD | Heart plus read insights from Dov Shamir, Ph.D., Head of Elementa Labs, on what makes this group of unique!

By Dov Shamir, PhD Head of Elementa Labs and Assistant Director, Entrepreneurship at MSIP Elementa Labs is pleased to announce its fifth cohort! Mount Sinai Innovation Partners (MSIP) recently shared how Elementa Labs provides an open and collaborative incubator with companies that have diverse fina...

02/13/2025

LinusBio, a precision exposomic medicine company whose foundational was developed at the Mount Sinai Health System, has launched ClearStrand-ASD, a diagnostic aid for spectrum disorder. The product aims to help physicians by ruling out the condition for young children and to inform decisions on early intervention and evaluations.

Learn more from BioSpace:

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--LinusBio, a leader in precision exposome medicine, today announced ClearStrand-ASD™, a first-of-its-kind diagnostic aid for autism spectrum disorder (ASD). ClearStrand-ASD is a biochemical test that identifies a molecular signature predictive of autism in a ...

02/11/2025

Meet the Elementa Labs Winter 2025 cohort!

MSIP's Dov Shamir, Head of Elementa Labs, shares insight into what makes this cohort unique and which fields they are focused on. Learn more below!

By Dov Shamir, PhD Head of Elementa Labs and Assistant Director, Entrepreneurship at MSIP Elementa Labs is pleased to announce its fifth cohort! Mount Sinai Innovation Partners (MSIP) recently shared how Elementa Labs provides an open and collaborative incubator with companies that have diverse fina...

02/06/2025

Are you interested in the opportunity to guide aspiring innovators and entrepreneurs in advancing new technology that can help patients? Join MSIP's Mentor Program and get involved with our growing community! https://ip.mountsinai.org/mentor-program/

02/05/2025

A study by Jennifer Lam-Rachlin, MD, Assistant Clinical Professor of Obstetrics, Gynecology and Reproductive Science at the Icahn School of Medicine at Mount Sinai and other researchers showed that can detect congenital heart defects on routine ultrasounds, paving the way for improved chances of survival for newborns. Learn more from Drugs.com:

Artificial intelligence (AI) can improve detection of congenital heart defects (CHDs) on routine prenatal ultrasounds, according to a study presented at The Pre

02/04/2025

The Icahn School of Medicine at Mount Sinai is collaborating with clinical stage company Purple Biotech, with researchers aiming to enhance tumor-specific immunity against multiple cancer types. Learn more:

REHOVOT, Israel, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, announced today that it has entered into a Research Col...

01/30/2025

A study by Erik Zhou, PhD, Instructor of Pediatrics at the Center for Child Health Services Research at the Icahn School of Medicine at Mount Sinai shows that parents who are vaccinated against vaccine are twice as likely to vaccinate their children against measles, mumps, and rubella (known as the MMR vaccine). Learn more from Healio:

Parents vaccinated against COVID-19 were almost twice as likely to vaccinate their child against measles, mumps and rubella compared with unvaccinated parents, according to a study published in American Journal of Public Health. The MMR vaccination rate among kindergarteners has fallen below 93% in....

01/21/2025

The FDA recently approved the drug mirikizumab to treat moderately to severely active Crohn’s disease (CD). Marla Dubinsky, MD, Chief of the Division of Pediatric Gastroenterology at the Mount Sinai Kravis Children's Hospital, offers insight into this new option for CD patients with HCPLive:

Dubinsky describes the evolution from anti-TNF therapies to IL-23 antagonists and the significance of mirikizumab’s approval for Crohn’s disease.

01/14/2025

Since 2021, Elementa Labs has brought startups into the Mount Sinai Health System innovation space, bolstering these companies with resources and access to experts, all for the goal of bringing new solutions to patients. Take a look at the trends and what's to come in 2025 as Elementa announces its next cohort soon!

By Dov Shamir, PhD Head of Elementa Labs and Assistant Director, Entrepreneurship at MSIP As we begin 2025, Mount Sinai Innovation Partners (MSIP) Elementa Labs is celebrating its four-year anniversary. In the coming weeks, MSIP will be announcing its fifth cohort and we wanted to take this as an op...

01/09/2025

Researchers at the Icahn School of Medicine at Mount Sinai have enhanced an (AI)-powered algorithm that improves the accuracy of diagnosing a common sleep disorder. Learn more from SciTechDaily:

Mount Sinai researchers have improved an AI tool for diagnosing a major sleep disorder from video sleep tests. Their approach, which captures the subtleties of sleep movements with enhanced accuracy, promises earlier detection of diseases like Parkinson's, ushering in more tailored treatments. A

01/01/2025

Happy New Year from MSIP!